– Can you provide more details about Devonian Health Group’s business objectives and growth strategies, particularly in the context of advancing botanical-based medicines and addressing unmet medical needs?
Devonian Health Group, a leading biotechnology company specializing in the development of botanical-based medicines, recently participated in Renmark’s Virtual Non-Deal Roadshow Series in Los Angeles. The company’s participation in this event marks an exciting opportunity to showcase its innovative products and advancements in the biotechnology sector.
The Renmark Virtual Non-Deal Roadshow Series is a renowned platform that connects investors, analysts, and industry professionals with high-growth companies. It offers an interactive virtual environment for companies to present their business strategies, milestones, and key achievements to a global audience. Devonian Health Group’s involvement in this event reflects its commitment to fostering investor relations and raising awareness about its cutting-edge research and development initiatives.
During the virtual roadshow, Devonian Health Group presented its proprietary technology, the Supra Molecular Platform (SMP), which serves as the foundation for its diverse portfolio of pharmaceutical and dermo-cosmetic products. The company’s innovative approach to drug delivery and therapeutic development has positioned it as a key player in the biopharmaceutical industry. By participating in the Roadshow Series, Devonian Health Group had the opportunity to highlight the potential of its SMP technology and its application in various therapeutic areas.
Key Highlights of Devonian Health Group’s Participation in the Virtual Non-Deal Roadshow Series:
Strategic Vision and Business Objectives: Devonian Health Group shared its strategic vision, emphasizing its commitment to advancing botanical-based medicines and addressing unmet medical needs. The company outlined its business objectives and growth strategies, highlighting its focus on commercializing novel therapies and expanding its global footprint.
Pipeline of Innovative Products: The virtual roadshow allowed Devonian Health Group to showcase its robust pipeline of innovative products, including its lead candidate, Thykamine™. This patented compound is being developed for the treatment of chronic inflammatory conditions, such as psoriasis and atopic dermatitis. The company also presented its dermo-cosmetic product line, highlighting the potential for synergies between pharmaceutical and skincare applications.
Scientific Advancements and Research Milestones: Devonian Health Group provided insights into the scientific advancements achieved through its research and development efforts. The company highlighted key milestones and achievements, including preclinical and clinical data supporting the efficacy and safety of its products. By sharing its research findings, Devonian Health Group demonstrated its dedication to evidence-based medicine and rigorous scientific validation.
Investor Engagement and Networking Opportunities: Participation in the Renmark Virtual Non-Deal Roadshow Series allowed Devonian Health Group to engage with a diverse audience of investors, analysts, and industry professionals. The company leveraged this opportunity to foster meaningful connections, communicate its value proposition, and address inquiries from potential investors. Through active participation and networking, Devonian Health Group reinforced its commitment to transparent communication and stakeholder engagement.
Opportunities for Collaboration and Partnerships: The virtual roadshow provided a platform for Devonian Health Group to explore potential collaborations, licensing opportunities, and strategic partnerships. The company showcased its openness to forging mutually beneficial relationships with stakeholders in the biopharmaceutical and healthcare sectors, emphasizing its collaborative approach to innovation and business development.
As Devonian Health Group continues to advance its portfolio of botanical-based medicines and dermatological products, its participation in the Renmark Virtual Non-Deal Roadshow Series serves as a testament to its dedication to transparency, innovation, and stakeholder engagement. The company’s commitment to advancing botanical-based medicines and addressing unmet medical needs is underscored by its strategic participation in industry events that facilitate meaningful dialogue and collaboration.
Devonian Health Group’s engagement in Renmark’s Virtual Non-Deal Roadshow Series in Los Angeles exemplifies its proactive approach to investor relations, business development, and scientific dissemination. This participation not only offers a platform to showcase the company’s innovative technologies and products, but also facilitates valuable networking opportunities and potential collaborations. As Devonian Health Group forges ahead with its mission to advance botanical-based medicines, its involvement in industry events of this nature reinforces its position as a leading biotechnology company with a commitment to driving meaningful impact in the healthcare landscape.
DEVONIAN TO PARTICIPATE IN RENMARK VIRTUAL NON-DEAL ROADSHOW
Quebec City, July 08, 2024— Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), has announced its participation in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series in Los Angeles on July 10, 2024. The purpose of this event is to discuss its latest investor presentation with stakeholders, investors, and other individual followers.
Event Details
The presentation will be led by Mr. Luc Gregoire, President & Chief Executive Officer of Devonian, covering the latest investor presentation followed by a live Question & Answer segment. Interested investors will need to register using the provided link. Although registration for the live event may be limited, access to the replay after the event will be available on the Company’s investor website.
Registration Link:
Wednesday, July 10, 2024: https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-tsx-v-gsd-otcqb-dvhgf-2024-07-10-110000
To ensure smooth connectivity, please access this link using the latest version of Google Chrome.
About Devonian
Devonian Health Group Inc. is a late-stage botanical pharmaceutical corporation with groundbreaking therapeutic approaches to targeting unmet medical needs. The company focuses on developing prescription botanical drugs for inflammatory autoimmune diseases like ulcerative colitis and atopic dermatitis, leveraging over 15 years of research. Devonian’s strategy is further supported by US FDA regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over traditional prescription medicines. Additionally, Devonian is involved in the development of high-value cosmeceutical products and owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies. The company was incorporated in 2015 and is headquartered in Québec, Canada, where it owns a state-of-the-art extraction facility with full traceability ‘from the seed to the pill’. Devonian is publicly traded on the TSX Venture Exchange (TSXV: GSD) and the OTCQB exchange (OTCQB: DVHGF).
For more information, visit www.groupedevonian.com
About Renmark Financial Communications Inc.
Founded in 1999, Renmark is a leading privately held full-service investor relations firm, providing services in investor relations, media relations, and web development to public companies listed on major North American exchanges. Our team of professionals enhance clients’ visibility within the retail market space on a daily basis, and we host live streaming Virtual Non-Deal Roadshows across North America and Europe.
Cautionary Note Regarding Forward-Looking Statements
All statements contained in this press release, including those relating to the impact of the roadshow, constitute “forward-looking information” within the meaning of certain securities laws, and are based on expectations, estimates, and projections as of the time of this press release. By their very nature, forward-looking statements involve inherent risks and uncertainties, and there can be no assurance that these assumptions will prove to be correct. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future.
Neither the Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Contacts
Devonian Health Group Inc.
Mr. Luc Grégoire
President and CEO
Telephone: 1 (450) 979-2916
E-mail: investors@groupedevonian.com
Renmark Financial Communications Inc.
Ben Ozerkevich
Telephone: (416) 644-2020 or (212) 812-7680
E-mail: bozerkevich@renmarkfinancial.com
www.renmarkfinancial.com